Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:01 11/05/2024 am IST			5-day change	1st Jan Change
0.524 ^USD	-3.23%		-6.60%	-50.57%

21/03	Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024
15/03	Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 10, 2023 at 03:27 am IST

Ensysce Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 2.69 million compared to USD 9.83 million a year ago. Basic loss per share from continuing operations was USD 0.87 compared to USD 61.58 a year ago.
For the nine months, net loss was USD 7.11 million compared to USD 18.68 million a year ago. Basic loss per share from continuing operations was USD 3.32 compared to USD 140.9 a year ago.

Latest news about Ensysce Biosciences, Inc.

Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024	21/03
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Ensysce Biosciences Announces Successful Meeting with Fda for Pf614-Mpar, A Next Generation Opioid with Overdose Protection	21/02	CI
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript	15/02	CI
Ensysce Shares Rally After FDA Feedback on Pain Medication	31/01	DJ
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain	31/01	CI
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR	24/01	DJ
Wall Street Set to Open Flat as Investors Eye Key Manufacturing Index	23/01	MT
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic	14/12	CI
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	28/11	CI
Ensysce Biosciences, Inc. announced that it has received $1.7 million in funding	28/11	CI
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study	16/11	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Ensysce Biosciences, Inc. announced that it expects to receive $1.7 million in funding	23/23/23	CI
Top Premarket Gainers	09/23/09	MT
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study	26/23/26	CI
HC Wainwright Adjusts Ensysce Biosciences Price Target to $7 From $9, Maintains Buy Rating	25/23/25	MT
Transcript : Ensysce Biosciences, Inc. - Special Call	21/23/21
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies	14/23/14	CI
Transcript : Ensysce Biosciences, Inc. - Shareholder/Analyst Call	24/23/24
Certain Common Stock of Ensysce Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 16-AUG-2023.	16/23/16	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol	08/23/08	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Ensysce Biosciences Closes $7 Million Public Offering	15/23/15	MT

Chart Ensysce Biosciences, Inc.

Duration

Period

More charts

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ensysce Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENSYSCE BIOSCIENCES, INC.	-50.57%	3.97M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research